Aging is commonly defined as a time-dependent loss of physiological integrity, leading to the decline and impair in organism functions and to the increase of risk for cancer and other major age-associated diseases, finally increasing vulnerability to death [1]. During the last decade the intensive search of anti-aging remedies has lead to the conclusion that both the insulin/IGF-like signaling (IIS) and nutrient response pathways such as the mechanistic target of rapamycin (MTOR) control aging and age-associated pathology in yeast, worms, insects and mammals [2-6]. mTOR complex 1 (mTORC1) is activated by insulin and related growth factors through phosphatidylinositol-3-OH kinase (PI(3)K) and AKT kinase signaling and suppressed by AMP-activated protein kinase (AMPK), a key sensor of cellular energy status. mTORC1 involved into promotion messenger RNA translation and protein synthesis through ribosomal protein S6 kinases (S6Ks) and 4E-BP protein, which in the hypophosphorylated form acts as a negative regulator of the cap-binding protein eIF4E. mTORC1 also stimulates lipid biosynthesis, inhibits autophagy, and through hypoxic response transcription factor HIF-1α regulates mitochondrial function and glucose metabolism. Rapamycin suppresses mTORC1 and also indirectly mTORC2 that leads glucose intolerance and abnormal lipid profile. Effects of biguanides and rapamycin on the senescence-associates secretory phenotype interfering with IKK-β/NF-κB – an important step in hypothalamic programming of systemic aging. Recent finding of suppressive effect of rapamycin on some parameters of brain aging in mice [7] and in senescence-accelerated OXYS rats [8] have shown that the drug controls multiple events related to aging. There are nine tentative hallmarks of aging in mammals, which may represent common denominators of aging in different organisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered cell-to-cell communication [1]. Rapamycin and metformin seem to influence all of them. Noteworthy, there is a significant similarity in the effects of rapamycin and metformin as anti-aging and anti-carcinogenic remedies. We believe that rapamycin and metformin are promising for premature prevention in humans.
References
- 1. Lopez-Otin C, et al. Cell. 2013; 152: 1194 -1217. [PubMed] .
- 2. Blagosklonny MV. Cell Cycle. 2010; 9: 3151 -3156. [PubMed] .
- 3. Anisimov VN, et al. Aging. Albany NY 2011; 3: 148 -157. [PubMed] .
- 4. Anisimov VN and Bartke A. Crit Rev Oncol Hematol. 2013; doi:pii:S1040-8428(13)00031-0.1016/j.critrevonc.2013.01.005 .
- 5. Harrison DE, et al. Nature. 2009; 460: 392 -396. [PubMed] .
- 6. Anisimov VN, et al. Cell Cycle. 2011; 10: 4230 -4236. [PubMed] .
- 7. Hallkoran J, et al. Neuroscience. 2012; 223: 102 -113. [PubMed] .
- 8. Kolosova NG, et al. Aging. Albany NY 2013; 5: 474 -484. [PubMed] .